WO2015019253A3 - Anti-dengue virus genetic vaccine based on the envelope protein ectodomains - Google Patents

Anti-dengue virus genetic vaccine based on the envelope protein ectodomains Download PDF

Info

Publication number
WO2015019253A3
WO2015019253A3 PCT/IB2014/063588 IB2014063588W WO2015019253A3 WO 2015019253 A3 WO2015019253 A3 WO 2015019253A3 IB 2014063588 W IB2014063588 W IB 2014063588W WO 2015019253 A3 WO2015019253 A3 WO 2015019253A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
envelope protein
genetic vaccine
vaccine based
domain
Prior art date
Application number
PCT/IB2014/063588
Other languages
French (fr)
Other versions
WO2015019253A2 (en
Inventor
Oscar Burrone
Marco Bestagno
Monica POGGIANELLA
Original Assignee
International Centre For Genetic Engineering And Biotechnology - Icgeb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre For Genetic Engineering And Biotechnology - Icgeb filed Critical International Centre For Genetic Engineering And Biotechnology - Icgeb
Publication of WO2015019253A2 publication Critical patent/WO2015019253A2/en
Publication of WO2015019253A3 publication Critical patent/WO2015019253A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention refers to a genetic vaccine for dengue virus of all serotypes or for any virus belonging to the Flavivirus genus. Said vaccine is based on the envelope protein E ectodomains, more in particular on the DIII domain of dengue virus or of other Flavivirus. A genetic construct encoding a fusion protein wherein said domain of envelope protein E is fused to a carboxyterminal domain from the constant region of an immunoglobulin is disclosed in the present invention. The use of said construct allows for an efficient secretion of the fusion protein from the cells and thus for a high antibody response.
PCT/IB2014/063588 2013-08-05 2014-07-31 Anti-dengue virus genetic vaccine based on the envelope protein ectodomains WO2015019253A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000458A ITRM20130458A1 (en) 2013-08-05 2013-08-05 ANTI-DENGUE VIRUS GENETIC VACCINE BASED ON THE ECTODOMINS OF THE PROTEIN ENVELOPE
ITRM2013A000458 2013-08-05

Publications (2)

Publication Number Publication Date
WO2015019253A2 WO2015019253A2 (en) 2015-02-12
WO2015019253A3 true WO2015019253A3 (en) 2015-05-28

Family

ID=49304201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/063588 WO2015019253A2 (en) 2013-08-05 2014-07-31 Anti-dengue virus genetic vaccine based on the envelope protein ectodomains

Country Status (2)

Country Link
IT (1) ITRM20130458A1 (en)
WO (1) WO2015019253A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190022210A1 (en) * 2015-11-06 2019-01-24 Victor G. Solodushko Novel platform dna vaccine
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CN108503696B (en) * 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 Zika virus subunit vaccine expressed by yeast cells
EP4010355A4 (en) * 2019-08-06 2024-02-21 Univ North Carolina Chapel Hill Methods and compositions for stabilized recombinant flavivirus e protein dimers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234951A1 (en) * 2001-07-16 2004-11-25 Lisset Hermida Cruz Chimeric chains that coding for proteins that induce effects directed against viruses
WO2009099716A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
WO2007034507A2 (en) 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
US7981431B2 (en) 2007-06-08 2011-07-19 National Health Research Institutes Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use
WO2008152652A2 (en) 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology A dengue envelope domain iii-based tetravalent protein vaccine
AU2009313714B2 (en) 2008-11-17 2016-05-19 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
BRPI0904020B8 (en) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz vaccine composition against the dengue virus, and kit
EP2571990A4 (en) 2010-05-21 2013-11-20 Univ Pittsburgh Universal dengue virus sequences and methods of use
EP2621525A4 (en) 2010-10-01 2015-01-14 Univ Rochester Flavivirus domain iii vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234951A1 (en) * 2001-07-16 2004-11-25 Lisset Hermida Cruz Chimeric chains that coding for proteins that induce effects directed against viruses
WO2009099716A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN YAPING ET AL: "Demonstration of binding of dengue virus envelope protein to target cells", JOURNAL OF VIROLOGY, vol. 70, no. 12, 1996, pages 8765 - 8772, XP002734187, ISSN: 0022-538X *
LI G ET AL: "Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 3281-3, 5-12, 17, 18, 20-22, no. 2, 25 October 2004 (2004-10-25), pages 274 - 281, XP004581380, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2004.07.025 *
PURDY D E ET AL: "Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 333, no. 2, 15 March 2005 (2005-03-15), pages 239 - 250, XP004757140, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2004.12.036 *
SARAH MURRELL ET AL: "Review of dengue virus and the development of a vaccine", BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 29, no. 2, 29 November 2010 (2010-11-29), pages 239 - 247, XP028136136, ISSN: 0734-9750, [retrieved on 20101210], DOI: 10.1016/J.BIOTECHADV.2010.11.008 *
STAROPOLI I ET AL: "Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein", JOURNAL OF VIROLOGICAL METHODS, vol. 56, no. 2, 1996, pages 179 - 189, XP002716233, ISSN: 0166-0934 *

Also Published As

Publication number Publication date
WO2015019253A2 (en) 2015-02-12
ITRM20130458A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
MX363533B (en) Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof.
MX2015008847A (en) Influenza virus immunogenic compositions and uses thereof.
MX2020003260A (en) Fc-receptor binding modified asymmetric antibodies and methods of use.
WO2015109124A3 (en) Immunomodulatory agents
MX2015011408A (en) Il-33 antagonists and uses thereof.
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
CA2924268C (en) Anti-alpha-synuclein antibodies and methods of use
WO2015018528A8 (en) Il-15 and il-15raplha sushi domain based modulokines
NZ628206A (en) Virus like particle composition
WO2011032161A3 (en) Vaccines directed to langerhans cells
MX2014012978A (en) Modified antibody regions and uses thereof.
WO2015021058A3 (en) Engineered proteins with a protease cleavage site
WO2015063611A3 (en) Albumin variants and uses thereof
CY1122214T1 (en) ANTIBODIES SPECIFIC TO TON FCRN
WO2015019253A3 (en) Anti-dengue virus genetic vaccine based on the envelope protein ectodomains
NZ631110A (en) Marker vaccine
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
IN2014MU01248A (en)
EA201791918A1 (en) MODIFICATION OF PROTEINS OF CELL-OWNERS
EA202092723A1 (en) COMPOSITIONS AND METHODS CONCERNING IMMUNE TOLERANCE
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX2019007252A (en) Methods and compositions for dengue virus vaccines.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14752430

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14752430

Country of ref document: EP

Kind code of ref document: A2